Home / About AMP/
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees.
Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.
The Association for
Molecular Pathology is a not-for-profit scientific society that advances
the clinical practice, science, and excellence of molecular and genomic
laboratory medicine through education, innovation, and advocacy to
enable highest quality health care.
The Association for Molecular Pathology seeks to be a global community of professionals that advances excellence in the clinical practice of molecular and genomic laboratory medicine through:
- Activities that foster innovative and transformative patient care and the translation of scientific discoveries into diagnostic tests and services.
- Education Programs that promote clinical laboratory testing of high quality and utility.
- Advocacy that supports the practice of molecular pathology to enhance patient care and address regulatory payment issues facilitate the adoption of innovative laboratory testing and technologies, including regulatory and payment issues.
- Activities that facilitate knowledge transfer and collaboration among professionals worldwide.
Quality Health Care Through Excellence in Clinical Molecular Testing
- Tests developed and performed by molecular laboratory
health care professionals can provide useful information that guides a
patent's treatment and tailors it to ensure the best response, thereby
improving health outcomes (precision medicine). AMP members improve
patients' access to high quality tests.
- Adherence to practice guidelines, such as with lung
cancer testing, leads to improved patient care. AMP develops guidelines
for the molecular pathology field and promotes best practices.
- Laboratory developed tests (LDTs) are often the standard
of care, the highest quality test available, and at times, the only
available testing option. Patient access to LDTs performed in CLIA
certified laboratories should be maintained and not hampered through
the promulgation of regulation. Additionally, these laboratories
provide an option to clinically confirm research findings and should be
utilized for this purpose.
- Molecular laboratory health care professionals should
have the necessary expertise and training to consider a patent's
medical history, clinical presentation and other relevant information
to determine the most appropriate test that will provide the most
useful information to the patent's healthcare providers.
- The vast majority of molecular pathology tests require a
professional interpretation for the results to be actionable by a
- Molecular pathology professionals are essential members of the clinical care team.
- AMP is committed to the training and education of its
members, molecular pathology-professionals-in-training, non-molecular
laboratory professionals, and clinicians through education events such
as its annual meeting and online offerings; co-sponsored sessions at
other organizations' events; and, by facilitating the ongoing work of
Molecular Genetic Pathology fellowship program directors.
Fostering the Global Community of Molecular Pathology Professionals
- AMP is distinguished by its collegial community, where
members support one another with the common goal of advancing the
science and implementation of high quality molecular diagnostics to
directly benefit patient care.
- AMP welcomes physicians, doctoral scientists, trainees,
technologists and those from varied settings such as academic and
community medical centers, government, and industry. AMP members benefit
from a supportive environment that fosters open learning and
collaboration. Advancing patient care worldwide through molecular
testing requires investment in member interactions, education
activities, and harmonizing standards where possible.
Collaboration to Advance Molecular Pathology
- AMP partners with other provider associations, patient
organizations, trade associations, coalitions, and other stakeholders
to educate their members, develop practice guidelines, and perform
other activities that facilitate the integration of molecular testing
for best patient care.
- The Association is an active member in coalitions in
support of improved reimbursement and coverage of laboratory tests,
appropriate oversight of laboratory tests, and advocating for policies
that benefit patient care.
- In light of similar interests and goals, AMP frequently
aligns with the broader pathology community to have a stronger voice in
its advocacy efforts.
Advocacy that Advances the Field and Practice of
Molecular Pathology, Protects Patients, and Improves the Adoption of
Innovative Technologies and Tests
- AMP actively engages policymakers as a trusted expert.
- Policies that encourage careers in molecular pathology are essential to the future of medicine.
- Reimbursement policies must provide patient access to appropriate testing and fair payment for services.
- Both local and consolidated settings can have value for testing in the best interest of patient care.
- Patents on naturally-occurring DNA obstruct patients' access to testing, hinder research and are barriers to innovation.
- Molecular pathology is comprised of physician and
non-physician molecular professionals, all of whom have essential roles
in providing high quality molecular testing. Appropriately qualified
doctoral, i.e., PhD, scientists should be legislatively deemed in the
U.S. to be Qualified Healthcare Providers, able to bill Medicare
directly for their molecular pathology interpretive services.
Innovation to Transform Patient Care
- AMP supports continued investment and research in molecular medicine.
- Discoveries in our understanding of the molecular basis of disease are opening the doors to new treatments and cures.
Molecular laboratory health care professionals play an
important role in both the research and development of these advances
and their integration into clinical practice.
- Investment in biomedical research is critical to forward
new discoveries that will transform patient care, prevent disease, and
lead to more effective treatments. AMP members provide critical
surveillance of infectious disease outbreaks, which is crucial to help
the public health system prepare for unanticipated epidemics and new
pandemics. They rapidly develop new diagnostic tests that assist public
health officials with preventing and controlling outbreaks.